Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Department of Health and Human Services
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should hav
Funding
Award size
Not specified
Type
Cooperative Agreement
Dates
Deadline
Next 90 days
Posted
10/15/2024
Closes
2026-10-14
Eligibility
Eligibility
State governmentsCounty governmentsNonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationPublic and State controlled institutions of higher educationNative American tribal organizations (other than Federally recognized tribal governments)Others (see text field entitled "Additional Information on Eligibility" for clarification)Native American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesSmall businessesIndependent school districtsSpecial district governmentsPrivate institutions of higher educationCity or township governmentsNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationFor profit organizations other than small businesses
Program
Funding area
Education - EDHealth - HL
Opportunity #
PAR-25-074
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov